The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 1, 2007, Pages 133-138

  Koh, Stephen C L ^a   Singh, K ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Endometrial PAI 1 2; Levonorgestrel; Menorrhagia; u PA receptor

Indexed keywords

D DIMER; LEVONORGESTREL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; HUMAN TISSUE; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; MENORRHAGIA; MENSTRUATION; METRORRHAGIA; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOELASTOGRAPHY;

ADULT; CONTRACEPTIVES, ORAL, SYNTHETIC; ENDOMETRIUM; ERYTHROCYTE INDICES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; FOLLOW-UP STUDIES; HEMATOCRIT; HEMOSTASIS; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; LONGITUDINAL STUDIES; MENORRHAGIA; MENSTRUATION; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE; THROMBELASTOGRAPHY; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 33845530204     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02243.x     Document Type: Article

References (34)

1. Van Eijkeren MA, Christiaens GCML, Sixma JJ, Haspels AA. Haemorrhagia: A review. Obstet Gynecol Survey 1989; 44: 421-9.
2. Royal College of Obstetricians and Gynaecologists (RCOG). The Initial Management of Menorrhagia-Evidence-Cased Clinical Guidelines. No 1. London: RCOG Press, 1998.
3. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel releasing intrauterine devices. Int J Gynecol Pathol 1986; 5: 235-41.
4. Andersson K, Rybo G. A comparative randomized study of intrauterine administration of levonorgestrel and tranexamic acid in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 690-4.
5. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: Efficacy versus acceptability. Contraception 1995; 51: 231-5.
6. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obst Gynaecol 1998; 105: 592-8.
7. Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, Nilsson CG. Open randomized study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998; 316: 1122-6.
8. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and levonorgestrel-releasing intrauterine device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879-83.
9. Prentice A. Commentary: Promising results but wider recruitment needed. BMJ 1998; 316: 1126.
10. Kadir RA, Economides DL, Sabin CA, Oweens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485-9.
11. Dilley A, Drews C, Miller C, Lally C, Austin H, Ramaswamy D, Lurye D, Evatt B. Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obst Gynecol 2001; 97: 630-6.
12. Krause M, Aygoren-Pursum E, Ehrenforth S, Ludwig G, Vigh Th, Bohme M, Scharrer I. Inherited and acquired coagulation disorders in women with menorrhagia. Abstract P1137. Thromb Haemost. Paris, France: XVIII Congress ISTH, 2001.
13. Philipp CS, Dilley A, Miller CH, Evattt B, Baranwal A, Schwartz R, Bachmann G, Saisi P. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 477-84.
14. Hallberg L, Hagdahl A, Nilsson L, Rybo G. Menstrual blood loss - a population study: Variation at different ages and attempts to define normality. Acta Obstet Gynecol 1966; 45: 320-51.
15. World Health Organization. A Selection of Important Health Indicators Recommended by WHO Programmes. Catalogue of Health Indicators. Geneva: WHO, 1996.
16. Koh SCL, Wong PC, Yuen R, Chua SE, Ng BL, Ratnam SS. Concentration of plasminogen activators and inhibitor in the human endometrium at different phases of the menstrual cycle. J Reprod Fert 1992; 96: 407-13.
17. Bonnar J, Kasonde K, Haddon M, Hassanein MK, Allington MJ. Fibrinolytic activity in utero and bleeding complications with intrauterine contraceptive devices. Br J Obstet Gynaecol 1976; 83: 160-4.
18. Foley ME, Jenkins DM, McNicol GP. Production of fibrinolytic enzymes by macrophages on intrauterine contraceptive devices. Br J Obst Gynaecol 1978; 85: 551-6.
19. Liedholm P, Sjoberg N-O, Srivasta K, Astedt B. No increase of the fibrinolytic activity of the human endometrium by progesterone-releasing IUD (Progestasert). Contraception 1976; 17: 531-6.
20. Bonnar J, Sheppard BL, Dockeray CJ. The haemostatic system and dysfunctional uterine bleeding. Res Clin Forums 1983; 5: 27-36.
21. Higman JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734-9.
22. Koh SCL, Yuen R, Viegas OAC, Chua SE, Ng BL, Sen DK, Ratnam SS. A plasmin generation method for the determination of tissue plasminogen activator (t-PA) activity in blood. Immunol Cell Biol 1989; 67: 197-203.
23. Koh SCL, Yuen WK, Chua SE, Ng BL, Arulkumaran S. Thromboelastographic determination of calcium threshold for blood coagulation in vitro. J Med Tech Assoc Thailand 1996; 24: 25-33.
24. Koh SCL, Yuen R, Viegas OAC, Ratnam SS. Plasma urokinase activity and antigen levels in normal males, females and in late pregnancy. Med Sci Res 1992; 20: 601-2.
25. Koh SCL, Yuen R, Viegas OAC, Chua SE, Ng BL, Sen DK, Ratnam SS. Plasma tissue plasminogen activator inhibitor (t-PAI) activity in normal subjects. Med Sci Res 1989; 17: 135-6.
26. Koh SCL, Prasad RNV, Fong YF. Hemostatic status and fibrinolytic potential at different phases of the menstrual cycle. Clin Appl Thrombos/ Hemostas 2005; 11: 295-301.
27. Cederblad G, Hahn L, Korsan-Bengtsen K, Pehrsson NG, Rybo G. Variation in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle. Haemostasis 1977; 6: 294-302.
28. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women. Effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82: 1456-61.
29. Unkeless JC, Gordon S, Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med 1974; 139: 834-50.
30. Granelli-Piperno A, Vasalli JD, Reich E. Secretion of plasminogen activator by human polymorphonuclear leucocytes. J Exp Med 1977; 146: 1693-706.
31. Casslen B, Urano S, Ny T. (PAI-1) antigen and mRNA levels in human endometrial stromal cells. Thromb Res 1 1992; 75-87.
32. Casslen B, Nordengren J, Gustavsson B, Nilbert M, Lund LR. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor. J Clin Endocrinol Metab 1995; 80: 2776-84.
33. Liedholm P, Srivasta K, Wingerup L, Astedt B. Higher fibrinolytic activity in human endometrium in direct contact with an IUD. Acta Obstet Gynecol Scand 1983; 62: 169-70.
34. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-24.